SCHEMBL23536123

SCHEMBL23536123

COCS(=O)(=O)c1ccc(CO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.52
CA1 P00915 4/20 0.52
CA12 O43570 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
MAOB P27338 1/20 0.46
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
MMP14 P50281 1/20 0.45
PTGS2 P35354 2/20 0.42
PSIP1 O75475 1/20 0.41
ADAMTS4 O75173 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20300431 0.83 CA2 (0.50) CA2CA1CA12CA4CA6
SCHEMBL23554972 0.82 CA2 (0.53) CA2MAOBPSIP1HTTNPSR1
SCHEMBL23536115 0.81 MAOB (0.43) MAOBPSIP1HTTNPSR1POLB
SCHEMBL23536140 0.81 MAOB (0.42) CA2MAOBPTGS2PSIP1HTT
SCHEMBL23370050 0.80 CA2 (0.52) CA2CA1CA12CA9MAOB
SCHEMBL709880 0.79 PSIP1 (0.63) CA2CA1CA12CA4CA6
SCHEMBL29948486 0.78 MAOB (0.40) MAOBPSIP1POLBALDH1A1SMN1; SMN2
SCHEMBL23535962 0.78 MAOB (0.40) MAOBPSIP1POLBALDH1A1SMN1; SMN2
SCHEMBL23555194 0.78 ALDH1A1 (0.57) CA2CA1CA12CA6CA5A
SCHEMBL1939365 0.76 PLCG1 (0.59) CA2CA1CA12CA9MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 CA2 294/4885CA1 1974/4885CA12 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.